Fred Hardwicke
Medical Oncology · Childress, TXNPI 1194713248
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,671 of the $2,011 with a category attached, or 83.1%. It is spread thinly across 26 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $987 and has fallen 81.4% since, to $183 in 2025. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 87 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$257
- AbbVie$242
- Merck$199
- Exelixis Inc.$171
- Astellas Pharma US Inc$151
- E.r. Squibb & Sons, L.L.C.$113
- plus $878 from 20 others
Across 1 payment — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1K
What the payments were for
- Food & beverage$1,67183%
- Education$34017%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 5 | $257 |
| AbbVie | 6 | $242 |
| Merck | 11 | $199 |
| Exelixis Inc. | 5 | $171 |
| Astellas Pharma US Inc | 4 | $151 |
| E.r. Squibb & Sons, L.L.C. | 10 | $113 |
| Amgen | 6 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $102 |
| Novartis | 5 | $99 |
| Genentech USA, Inc. | 5 | $86 |
| Pfizer | 4 | $64 |
| Bristol Myers Squibb | 3 | $62 |
| AstraZeneca(2 entities) | 2 | $61 |
| Gilead | 3 | $46 |
| Tersera Therapeutics LLC | 2 | $37 |
| Bayer | 2 | $32 |
| Eisai Inc. | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
| Sanofi | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Incyte Corporation | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $16 |
| EMD Serono, Inc. | 1 | $13 |
| Rigel Pharmaceuticals, Inc. | 1 | $13 |
| Array Biopharma Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,011 in reported general payments places this provider in the 35th percentile of 495 medical oncology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 34 | $596,724 |
| NinlaroIxazomib Citrate | 15 | $292,511 |
| RevlimidLenalidomide | 11 | $196,190 |
| EliquisApixaban | 14 | $8,049 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 46 | $2,019 |
| Hydromorphone Hcl | 12 | $414 |
| Tamoxifen Citrate | 22 | $404 |
| Dexamethasone | 16 | $382 |
| Ondansetron OdtOndansetron | 11 | $296 |
| Levothyroxine Sodium | 37 | $206 |
| Raloxifene Hcl | 12 | $172 |
| Hydroxyzine Hcl | 12 | $116 |
| Letrozole | 19 | $108 |
| Acyclovir | 13 | $108 |
| Promethazine Hcl | 12 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $21 | $596,72434 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $102 | $292,51115 claims |
| Bristol Myers SquibbRevlimid | $62 | $196,19011 claims |
| PfizerEliquis | $64 | $8,04914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Childress
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
- Sue EckhardtAustin$1.5M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Maen AbdelrahimHouston$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.